EssilorLuxottica S.A.
Designs, manufactures and distributes ophthalmic lenses, frames, sunglasses, diagnostic imaging equipment and eyecare instruments globally under brands including Ray-Ban, Oakley and Essilor.
As of Jul 17, 2026
Executive summary
EssilorLuxottica is the world's largest eyewear company, combining lens manufacturing with retail distribution through brands including Ray-Ban and Sunglass Hut. The stock is trading with a bearish technical bias at €166.70 after a one-year decline of 29.6%, reflecting substantial shareholder losses over that period. Market capitalisation stands at €77.9 billion.
Price history
As of Jul 17, 2026
Performance
-1.65%
-2.74%
-6.14%
-17.37%
-36.78%
-29.58%
As of Jul 17, 2026
Technical indicators
- 43.8
- -0.16Bearish
- 50: 172.71 · 200: 230.43Bearish
- €162.65 / €177.95
Technical Bias
Bearish lean
EssilorLuxottica's technical setup is bearish. The MACD is in negative territory and the 50-day moving average (€172.71) sits below the 200-day (€230.43), both signalling downward momentum, whilst the RSI reads neutral at 43.8. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- €77.9B
- 34.04
- €4.98
- 8.13%
- +9.4%
- €3.77B
- 0.55
- €160.60 – €316.32
- 2.38%
- May 5, 2026
- Jul 28, 2026 (10 days)
As of Jul 17, 2026
Upcoming catalysts
- Earnings report
As of Jul 17, 2026
Latest news
As of Jul 17, 2026
Short-term outlook
Over the next few weeks, EssilorLuxottica's chart leans bearish, with the MACD negative and price sitting well below both the 50-day (€172.71) and 200-day (€230.43) averages, though RSI at 43.8 is neutral rather than oversold. Watch the €162.65 support and €177.95 resistance as the key markers, especially after the -6.1% pullback over the past month, with no earnings catalyst until July 2026.
Medium-term outlook
EssilorLuxottica continues to grow revenue at a healthy 9.4% year-on-year clip, with an 8.1% profit margin and a 2.4% dividend yield offering some income support. That said, the stock's premium valuation at a 34.04 P/E leaves little room for error, and the current bearish technical lean suggests the next few quarters could see the shares digest that growth before any renewed upside.
Key risks
- The share price sits near its 52-week low of €166.70, far below the €316.32 high, which points to significant negative momentum that may concern investors.
- A price-to-earnings ratio of 34.04 is relatively rich, meaning the stock could be more sensitive to any disappointment in future earnings.
- The profit margin of 8.1% is fairly modest, leaving limited buffer if costs rise or pricing comes under pressure.
- Competition in the ophthalmology and eyewear space is intensifying, with EssilorLuxottica named alongside Alcon, Bausch + Lomb, and over 20 other players in recent market coverage.
About EssilorLuxottica S.A.
EssilorLuxottica S.A. is a French healthcare group listed on Euronext Paris under the ticker EL, operating within the medical instruments and supplies industry. Formed through the merger of eyewear giant Luxottica and lens specialist Essilor, the company holds a leading position in the global eyewear market, spanning design, manufacture and distribution of glasses, lenses and related eye care products. With a market capitalisation of €77.9 billion, it stands as one of the largest players in its sector worldwide.
The company's key figures give a snapshot of how the market currently values it. A price-to-earnings ratio of 34.04 suggests investors are pricing in solid expectations for future earnings. Meanwhile, a dividend yield of +2.4% offers shareholders a modest income stream alongside any share price movement, reflecting the group's established, cash-generating position within the healthcare space.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.